Prednisolone, cytosine arabinoside, lomustine (CCNU), etoposide and thioguanine (PACET) combination chemotherapy for relapsed or refractory non-Hodgkin lymphoma

John W. Sweetenham, J. J. McKendrick, Graham M. Mead, J. Michael A. Whitehouse

Research output: Contribution to journalArticle

3 Scopus citations


27 patients with relapsed/refractory non-Hodgkin lymphoma (NHL) received combination chemotherapy with prednisolone, cytosine arabinoside, lomustine (CCNU), etoposide and thioguanine (PACET). 25 patients are evaluable for response. 7 (26%) obtained a complete response and one (4%) a partial response. The median survival for the entire group was 6 months. 2 patients are currently alive without disease, 1 of whom has received further therapy. The regimen was intensely myelosuppressive, but was well tolerated. The complete response rate and median survival figures are comparable to previous studies of salvage therapy confirming the poor prognosis for relapsed NHL and emphasising the need for prospective randomised studies.

Original languageEnglish (US)
Pages (from-to)190-192
Number of pages3
JournalEuropean Journal of Cancer
Issue number2
Publication statusPublished - 1993
Externally publishedYes


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this